Table 1 Baseline characteristics of the population before and after PSM
Variables | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
Open (n = 87) | VATS (n = 39) | P | Open (n = 27) | VATS (n = 27) | P | |
Age, Median (IQR) | 56.0 (48.5, 63.0) | 58.0 (47.5, 65.0) | 0.714 | 56.0 (49.5, 64.0) | 58.0 (45.5, 65.5) | 0.828 |
Sex, n (%) | 0.108 | 1.000 | ||||
Female | 32 (36.8) | 8 (20.5) | 5 (18.5) | 5 (18.5) | ||
Male | 55 (63.2) | 31 (79.5) | 22 (81.5) | 22 (81.5) | ||
Insurance, n (%) | 0.132 | 0.324 | ||||
Resident | 37 (42.5) | 11 (28.2) | 12 (44.4) | 6 (22.2) | ||
Employee | 23 (26.4) | 18 (46.2) | 7 (25.9) | 12 (44.4) | ||
Self-financed | 5 (5.7) | 3 (7.7) | 2 (7.4) | 2 (7.4) | ||
Non local | 22 (25.3) | 7 (17.9) | 6 (22.2) | 7 (25.9) | ||
Symptom, n (%) | 0.096 | 0.372 | ||||
Physical examination | 21 (24.1) | 17 (43.6) | 10 (37) | 7 (25.9) | ||
Chest pain | 32 (36.8) | 14 (35.9) | 9 (33.3) | 12 (44.4) | ||
Respiratory symptoms | 18 (20.7) | 5 (12.8) | 2 (7.4) | 5 (18.5) | ||
Other compression symptoms | 16 (18.4) | 3 (7.7) | 6 (22.2) | 3 (11.1) | ||
Myasthenia gravis, n (%) | 0.310 | 1.000 | ||||
No | 87 (100) | 38 (97.4) | 27 (100) | 26 (96.3) | ||
Yes | 0 (0) | 1 (2.6) | 0 (0) | 1 (3.7) | ||
ECOG, n (%) | 0.050 | 0.863 | ||||
0 | 21 (24.1) | 18 (46.2) | 10 (37) | 8 (29.6) | ||
1 | 55 (63.2) | 17 (43.6) | 14 (51.9) | 15 (55.6) | ||
2 | 11 (12.6) | 4 (10.3) | 3 (11.1) | 4 (14.8) | ||
ACCI, n (%) | 0.614 | 0.506 | ||||
0 | 19 (21.8) | 8 (20.5) | 6 (22.2) | 7 (25.9) | ||
1 | 31 (35.6) | 10 (25.6) | 10 (37) | 6 (22.2) | ||
2 | 25 (28.7) | 13 (33.3) | 6 (22.2) | 10 (37) | ||
≥ 3 | 12 (13.8) | 8 (20.5) | 5 (18.5) | 4 (14.8) | ||
Pulmonary function, n (%) | 0.202 | 0.715 | ||||
Normal | 51 (58.6) | 21 (53.8) | 15 (55.6) | 17 (63) | ||
Mild | 21 (24.1) | 15 (38.5) | 7 (25.9) | 8 (29.6) | ||
Moderate | 13 (14.9) | 2 (5.1) | 4 (14.8) | 1 (3.7) | ||
Severe | 2 (2.3) | 1 (2.6) | 1 (3.7) | 1 (3.7) | ||
Tumor size (cm), Median (IQR) | 6.4 (4.9, 8.2) | 4.3 (3.4, 5.2) | < 0.001 | 5.0 ± 2.0 | 4.9 ± 1.6 | 0.921 |
Masaoka-Koga stage, n (%) | 0.031 | 0.666 | ||||
I-IIA | 5 (5.7) | 7 (17.9) | 3 (11.1) | 5 (18.5) | ||
IIB | 14 (16.1) | 12 (30.8) | 8 (29.6) | 7 (25.9) | ||
IIIA | 27 (31) | 8 (20.5) | 8 (29.6) | 4 (14.8) | ||
IIIB | 26 (29.9) | 5 (12.8) | 4 (14.8) | 5 (18.5) | ||
IVA | 1 (1.1) | 1 (2.6) | 0 (0.0) | 0 (0.0) | ||
IVB | 14 (16.1) | 6 (15.4) | 4 (14.8) | 6 (22.2) | ||
Pathology, n (%) | 0.308 | 0.326 | ||||
Squamous carcinoma | 57 (65.5) | 26 (66.7) | 23 (85.2) | 19 (70.4) | ||
Adenocarcinoma | 9 (10.3) | 2 (5.1) | ||||
Sarcomatoid carcinoma | 4 (4.6) | 0 (0) | ||||
Epithelial myoepithelial carcinoma | 1 (1.1) | 0 (0) | ||||
Small cell carcinoma | 2 (2.3) | 2 (5.1) | 4 (14.8) | 8 (29.6) | ||
Large cell carcinoma | 0 (0) | 1 (2.6) | ||||
Carcinoid | 5 (5.7) | 2 (5.1) | ||||
Atypical carcinoid | 8 (9.2) | 3 (7.7) | ||||
Neuroendocrine carcinoma,NOS | 1 (1.1) | 3 (7.7) | ||||
Chemotherapy, n (%) | 0.238 | 1.000 | ||||
No | 16 (18.4) | 12 (30.8) | 9 (33.3) | 8 (29.6) | ||
Neoadjuvant | 2 (2.3) | 0 (0) | 18 (66.7) | 19 (70.4) | ||
Adjuvant | 69 (79.3) | 27 (69.2) | ||||
Radiotherapy, n (%) | 0.680 | 0.773 | ||||
No | 22 (25.3) | 11 (28.2) | 8 (29.6) | 10 (37) | ||
Neoadjuvant | 3 (3.4) | 0 (0) | 19 (70.4) | 17 (63.0) | ||
Adjuvant | 62 (71.3) | 28 (71.8) | ||||
Immunotherapy, n (%) | 0.103 | 1.000 | ||||
No | 76 (87.4) | 38 (97.4) | 26 (96.3) | 26 (96.3) | ||
Yes | 11 (12.6) | 1 (2.6) | 1 (3.7) | 1 (3.7) | ||